Last reviewed · How we verify
Liquid Palivizumab
Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells.
Palivizumab is a monoclonal antibody that binds to the fusion (F) protein on the surface of respiratory syncytial virus (RSV), preventing viral attachment and entry into host cells. Used for Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients, including premature infants and children with congenital heart disease or chronic lung disease.
At a glance
| Generic name | Liquid Palivizumab |
|---|---|
| Also known as | Synagis |
| Sponsor | MedImmune LLC |
| Drug class | Monoclonal antibody (RSV F protein inhibitor) |
| Target | RSV F (fusion) protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Palivizumab neutralizes RSV by targeting the F protein, which is essential for viral fusion with respiratory epithelial cells. By blocking this protein, the antibody prevents RSV from infecting cells and reduces viral replication. This passive immunization approach provides immediate protection against RSV infection.
Approved indications
- Prevention of respiratory syncytial virus (RSV) disease in high-risk infants and young children, including those with congenital heart disease, chronic lung disease, or immunodeficiency
Common side effects
- Injection site reaction
- Fever
- Upper respiratory tract infection
- Otitis media
Key clinical trials
- Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease (NA)
- Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV (PHASE1)
- Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) (PHASE4)
- Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
- Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season (PHASE2)
- A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liquid Palivizumab CI brief — competitive landscape report
- Liquid Palivizumab updates RSS · CI watch RSS
- MedImmune LLC portfolio CI